CA2734519C - Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel - Google Patents
Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel Download PDFInfo
- Publication number
- CA2734519C CA2734519C CA2734519A CA2734519A CA2734519C CA 2734519 C CA2734519 C CA 2734519C CA 2734519 A CA2734519 A CA 2734519A CA 2734519 A CA2734519 A CA 2734519A CA 2734519 C CA2734519 C CA 2734519C
- Authority
- CA
- Canada
- Prior art keywords
- sample
- seq
- nos
- nucleic acid
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 98
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 43
- 208000035475 disorder Diseases 0.000 title abstract description 15
- 101150098072 20 gene Proteins 0.000 title description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 84
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 16
- 238000002626 targeted therapy Methods 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 106
- 102000039446 nucleic acids Human genes 0.000 claims description 93
- 108020004707 nucleic acids Proteins 0.000 claims description 93
- 238000011282 treatment Methods 0.000 claims description 40
- 238000001574 biopsy Methods 0.000 claims description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 26
- 229960000598 infliximab Drugs 0.000 claims description 18
- 238000009175 antibody therapy Methods 0.000 claims description 12
- 210000001072 colon Anatomy 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 229940068196 placebo Drugs 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 157
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 82
- 239000000047 product Substances 0.000 description 51
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 238000009396 hybridization Methods 0.000 description 45
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 229920001184 polypeptide Polymers 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 230000004044 response Effects 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 238000003491 array Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000005557 antagonist Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 239000002773 nucleotide Chemical group 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000003252 repetitive effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 7
- 108091027757 Deoxyribozyme Proteins 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002974 pharmacogenomic effect Effects 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- -1 methylimino Chemical group 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 5
- 102100027309 Cyclic AMP-responsive element-binding protein 5 Human genes 0.000 description 5
- 102100040907 Glycerol kinase 3 Human genes 0.000 description 5
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 5
- 101000726193 Homo sapiens Cyclic AMP-responsive element-binding protein 5 Proteins 0.000 description 5
- 101001040119 Homo sapiens Glycerol kinase 3 Proteins 0.000 description 5
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 5
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 5
- 108090000630 Oncostatin M Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 101150096316 5 gene Proteins 0.000 description 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 4
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
- 101710140859 E3 ubiquitin ligase TRAF3IP2 Proteins 0.000 description 4
- 102100026620 E3 ubiquitin ligase TRAF3IP2 Human genes 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 3
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 3
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 3
- 101000984198 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 1 Proteins 0.000 description 3
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 3
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102100025587 Leukocyte immunoglobulin-like receptor subfamily A member 1 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100022781 ATP-sensitive inward rectifier potassium channel 15 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100024508 Ficolin-1 Human genes 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101001047184 Homo sapiens ATP-sensitive inward rectifier potassium channel 15 Proteins 0.000 description 2
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 2
- 101001052785 Homo sapiens Ficolin-1 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 2
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000998855 Homo sapiens Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 101000879840 Homo sapiens Serglycin Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 description 2
- 102100033995 Long-chain-fatty-acid-CoA ligase 1 Human genes 0.000 description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100031942 Oncostatin-M Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108010066717 Q beta Replicase Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100037344 Serglycin Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000004665 defense response Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000004783 epithelial tight junction Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- FDFPSNISSMYYDS-UHFFFAOYSA-N 2-ethyl-N,2-dimethylheptanamide Chemical compound CCCCCC(C)(CC)C(=O)NC FDFPSNISSMYYDS-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- 108091005560 ADGRG3 Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100040037 Adhesion G protein-coupled receptor G3 Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100029406 Aquaporin-7 Human genes 0.000 description 1
- 101100018714 Arabidopsis thaliana ILR2 gene Proteins 0.000 description 1
- 108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102100028699 C-type lectin domain family 4 member E Human genes 0.000 description 1
- 102100040531 CKLF-like MARVEL transmembrane domain-containing protein 2 Human genes 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- 101100540159 Candida albicans (strain SC5314 / ATCC MYA-2876) TFP1 gene Proteins 0.000 description 1
- 102100034786 Cell migration-inducing and hyaluronan-binding protein Human genes 0.000 description 1
- 102100024325 Contactin-3 Human genes 0.000 description 1
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100037573 Dual specificity protein phosphatase 12 Human genes 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101150104463 GOS2 gene Proteins 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 102100033424 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100040139 Glycosyltransferase 1 domain-containing protein 1 Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000771402 Homo sapiens Aquaporin-7 Proteins 0.000 description 1
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 1
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000766921 Homo sapiens C-type lectin domain family 4 member E Proteins 0.000 description 1
- 101000749427 Homo sapiens CKLF-like MARVEL transmembrane domain-containing protein 2 Proteins 0.000 description 1
- 101000945881 Homo sapiens Cell migration-inducing and hyaluronan-binding protein Proteins 0.000 description 1
- 101000909517 Homo sapiens Contactin-3 Proteins 0.000 description 1
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 description 1
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 description 1
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 1
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 1
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000997966 Homo sapiens Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Proteins 0.000 description 1
- 101001037042 Homo sapiens Glycosyltransferase 1 domain-containing protein 1 Proteins 0.000 description 1
- 101001079904 Homo sapiens Hyaluronan and proteoglycan link protein 1 Proteins 0.000 description 1
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 description 1
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 description 1
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 1
- 101000577891 Homo sapiens Myeloid cell nuclear differentiation antigen Proteins 0.000 description 1
- 101000582936 Homo sapiens Pleckstrin Proteins 0.000 description 1
- 101000829538 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 15 Proteins 0.000 description 1
- 101000610543 Homo sapiens Prokineticin-2 Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101000870953 Homo sapiens RAS guanyl-releasing protein 4 Proteins 0.000 description 1
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 1
- 101000837008 Homo sapiens Sigma intracellular receptor 2 Proteins 0.000 description 1
- 101000891084 Homo sapiens T-cell activation Rho GTPase-activating protein Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000786319 Homo sapiens Zinc finger BED domain-containing protein 3 Proteins 0.000 description 1
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 description 1
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
- 241001575980 Mendoza Species 0.000 description 1
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 1
- 101100153533 Mus musculus Ltbr gene Proteins 0.000 description 1
- 102100027994 Myeloid cell nuclear differentiation antigen Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000032234 No therapeutic response Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100023229 Polypeptide N-acetylgalactosaminyltransferase 15 Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100040125 Prokineticin-2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 102100033445 RAS guanyl-releasing protein 4 Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101001069900 Rattus norvegicus Growth-regulated alpha protein Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 1
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108091006737 SLC22A4 Proteins 0.000 description 1
- 101100316793 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VMA1 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100036928 Solute carrier family 22 member 4 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 102100040346 T-cell activation Rho GTPase-activating protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 102100025798 Zinc finger BED domain-containing protein 3 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 210000005204 intestinal dendritic cell Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- XTGGILXPEMRCFM-UHFFFAOYSA-N morpholin-4-yl carbamate Chemical compound NC(=O)ON1CCOCC1 XTGGILXPEMRCFM-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003756 response to other organism Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9296608P | 2008-08-29 | 2008-08-29 | |
| US61/092,966 | 2008-08-29 | ||
| PCT/US2009/055323 WO2010025340A2 (en) | 2008-08-29 | 2009-08-28 | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2734519A1 CA2734519A1 (en) | 2010-03-04 |
| CA2734519C true CA2734519C (en) | 2018-11-13 |
Family
ID=41722298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2734519A Active CA2734519C (en) | 2008-08-29 | 2009-08-28 | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100069256A1 (enExample) |
| EP (1) | EP2329259B1 (enExample) |
| JP (1) | JP5586607B2 (enExample) |
| CN (1) | CN102165315B (enExample) |
| AU (1) | AU2009285644B2 (enExample) |
| BR (1) | BRPI0917379A2 (enExample) |
| CA (1) | CA2734519C (enExample) |
| DK (1) | DK2329259T3 (enExample) |
| ES (1) | ES2581774T3 (enExample) |
| IL (1) | IL211154A0 (enExample) |
| RU (1) | RU2011111748A (enExample) |
| WO (1) | WO2010025340A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008028044A2 (en) * | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| WO2016063204A1 (en) * | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
| WO2016092045A1 (en) * | 2014-12-11 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for predicting medically refractory acute severe colitis |
| GB2547406A (en) * | 2015-11-20 | 2017-08-23 | Folkersen Lasse | Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response |
| WO2017175228A1 (en) | 2016-04-06 | 2017-10-12 | Technion Research & Development Foundation Limited | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies |
| KR102481305B1 (ko) | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| WO2017216206A1 (en) * | 2016-06-14 | 2017-12-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting acute severe colitis treatment response |
| CA3064529C (en) | 2017-05-31 | 2021-12-14 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in crohn's disease patients |
| EP3821246A4 (en) * | 2018-07-15 | 2022-06-22 | Rambam Med-Tech Ltd. | Determining responders to inflammation treatment |
| US20210355538A1 (en) * | 2018-10-19 | 2021-11-18 | Children's Hospital Medical Center | Use of mucosal transcriptomes for assessing severity of ulcerative colitis and responsiveness to treatment |
| JP7657714B2 (ja) * | 2018-11-15 | 2025-04-07 | ヤンセン バイオテツク，インコーポレーテツド | 炎症性腸疾患の治療に対する応答を予測するための方法及び組成物 |
| CN114015689B (zh) * | 2021-10-26 | 2024-06-07 | 江苏大学 | 一种特异性抑制GOS2基因表达的shRNA序列及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| JP3645903B2 (ja) | 1992-03-04 | 2005-05-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 比較ゲノムハイブリダイゼーション（ｃｇｈ） |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| CA2174140C (en) | 1993-10-28 | 2004-04-06 | Kenneth L. Beattie | Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US5723320A (en) | 1995-08-29 | 1998-03-03 | Dehlinger; Peter J. | Position-addressable polynucleotide arrays |
| US5843655A (en) | 1995-09-18 | 1998-12-01 | Affymetrix, Inc. | Methods for testing oligonucleotide arrays |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
| ATE234674T1 (de) | 1996-11-14 | 2003-04-15 | Affymetrix Inc | Chemische amplifizierung zur synthese von musterordnungen |
| WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
| US6197503B1 (en) | 1997-11-26 | 2001-03-06 | Ut-Battelle, Llc | Integrated circuit biochip microsystem containing lens |
| US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| US6087103A (en) | 1998-03-04 | 2000-07-11 | Lifespan Biosciences, Inc. | Tagged ligand arrays for identifying target-ligand interactions |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| US6093370A (en) | 1998-06-11 | 2000-07-25 | Hitachi, Ltd. | Polynucleotide separation method and apparatus therefor |
| US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US6174684B1 (en) | 1999-08-11 | 2001-01-16 | Trustees Of The University Of Pennsylvania | CYP3A4 NFSE variant and methods of use therefore |
| EP1356088A2 (en) | 2000-06-07 | 2003-10-29 | Baylor College of Medicine | Compositions and methods for array-based nucleic acid hybridization |
| US20040077020A1 (en) * | 2001-11-30 | 2004-04-22 | Mannick Elizabeth E. | Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis |
| JP2006504406A (ja) | 2002-06-28 | 2006-02-09 | セントカー・インコーポレーテツド | 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用 |
| AU2005300688B2 (en) * | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| WO2007103823A2 (en) | 2006-03-03 | 2007-09-13 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
| WO2008028044A2 (en) * | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| WO2008137383A2 (en) * | 2007-04-30 | 2008-11-13 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel |
| EP2326731B1 (en) * | 2008-08-25 | 2013-11-13 | Janssen Biotech, Inc. | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
-
2009
- 2009-08-28 CN CN200980134148.1A patent/CN102165315B/zh active Active
- 2009-08-28 DK DK09810643.8T patent/DK2329259T3/en active
- 2009-08-28 AU AU2009285644A patent/AU2009285644B2/en active Active
- 2009-08-28 RU RU2011111748/15A patent/RU2011111748A/ru unknown
- 2009-08-28 WO PCT/US2009/055323 patent/WO2010025340A2/en not_active Ceased
- 2009-08-28 JP JP2011525223A patent/JP5586607B2/ja active Active
- 2009-08-28 EP EP09810643.8A patent/EP2329259B1/en active Active
- 2009-08-28 ES ES09810643.8T patent/ES2581774T3/es active Active
- 2009-08-28 CA CA2734519A patent/CA2734519C/en active Active
- 2009-08-28 BR BRPI0917379A patent/BRPI0917379A2/pt not_active Application Discontinuation
- 2009-08-31 US US12/550,703 patent/US20100069256A1/en not_active Abandoned
-
2011
- 2011-02-10 IL IL211154A patent/IL211154A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2329259B1 (en) | 2016-04-20 |
| IL211154A0 (en) | 2011-04-28 |
| EP2329259A4 (en) | 2012-05-16 |
| CN102165315A (zh) | 2011-08-24 |
| JP5586607B2 (ja) | 2014-09-10 |
| AU2009285644A1 (en) | 2010-03-04 |
| WO2010025340A3 (en) | 2010-04-22 |
| EP2329259A2 (en) | 2011-06-08 |
| RU2011111748A (ru) | 2012-10-10 |
| ES2581774T3 (es) | 2016-09-07 |
| AU2009285644B2 (en) | 2015-08-20 |
| CA2734519A1 (en) | 2010-03-04 |
| US20100069256A1 (en) | 2010-03-18 |
| BRPI0917379A2 (pt) | 2015-11-17 |
| DK2329259T3 (en) | 2016-05-09 |
| CN102165315B (zh) | 2014-06-18 |
| WO2010025340A2 (en) | 2010-03-04 |
| JP2012501452A (ja) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2734519C (en) | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel | |
| EP2326731B1 (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders | |
| US7943310B2 (en) | Methods for assessing response to therapy in subjects having ulcerative colitis | |
| US20080293582A1 (en) | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel | |
| US20140011704A1 (en) | Markers and Methods for Assessing and Treating Crohn's Disease and Related Disorders | |
| US20100331209A1 (en) | Markers and methods for assessing and treating severe or persistant asthma and tnf related disorders | |
| US20110294686A1 (en) | Egfr inhibitor therapy responsiveness | |
| EP2148943B1 (en) | Methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel | |
| HK1157410B (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140826 |